NDAORALTABLET, EXTENDED RELEASE
Approved
Jan 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
DESVENLAFAXINE (desvenlafaxine fumarate) by Fosun Pharma is unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake. First approved in 2014.
Drug data last refreshed 58m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Desvenlafaxine fumarate is an oral extended-release serotonin-norepinephrine reuptake inhibitor (SNRI) approved for major depressive disorder. It works by inhibiting the reuptake of serotonin and norepinephrine in the central nervous system, with high selectivity and no significant affinity for other receptor types. The drug achieves steady-state concentrations within 4-5 days with once-daily dosing and linear, predictable pharmacokinetics.
Peak
Product is at peak commercial maturity with moderate competitive pressure (30%), suggesting stable but not expanding market opportunities for brand and sales roles.
Mechanism of Action
unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake. Non-clinical studies have shown that desvenlafaxine is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). 12.2…
Worked on DESVENLAFAXINE at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.